Renin inhibition and microalbuminuria development: Meaningful predictor of kidney disease progression

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 437-443

  De Silva, Lalitha ^a   Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

aliskiren; direct renin inhibition; hypertension; microalbuminuria

Indexed keywords

ALISKIREN; IRBESARTAN; LOSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HORMONE INHIBITION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN;

EID: 77955923009     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833d14c3     Document Type: Review

References (38)

1. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
2. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of End-points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18:1540-1546.
3. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
4. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53:49-57.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
6. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24:1663-1671.
7. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, et al. Update on micro-albuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006; 15:631-636.
8. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121:e46-e215.
9. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
10. Weir MR. Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. Clin J Am Soc Nephrol 2009; 4:2045-2050.
11. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2:581-590.
12. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006; 17:2106-2111.
13. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969-975.
14. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73:1419-1425.
15. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004; 17:986-993.
16. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
17. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285-2293.
18. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31:462-465.
19. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31:469-470.
20. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173-1181.
21. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
22. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49:12-26.
23. deZeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
24. Parving H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner and Rector's The Kidney. 8th ed. Philadelphia: Elsevier; 2008. pp. 1265-1298.
25. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
26. Bakris GL, Ritz E.The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Nephrology (Carlton) 2009; 14:49-51.
27. Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121:332-340.
28. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 2008; 10:130-139.
29. Agarwal R, Kariyanna SS, Light RP. Circadian blood pressure classification scheme and the health of patients with chronic kidney disease. Am J Nephrol 2009; 30:536-546.
30. Peterson GE, De Backer T, Gabriel A, et al. Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension 2007; 50:1033-1039.
31. Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant 2009; 24:2400-2406.
32. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446.
33. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldos-terone Syst 2006; 7:3-14.
34. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32:387-392.
35. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study [abstract]. Circulation 2009; 120:S45a-S453.
36. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368:1449-1456.
37. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
38. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.